Diffuse large B cell lymphoma laboratory tests: Difference between revisions
Jump to navigation
Jump to search
Mahshid |
|||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Diffuse large B cell lymphoma}} | {{Diffuse large B cell lymphoma}} | ||
DLBCL require a complete work-up includes immunophenotypic analysis, cytogenetic analysis (conventional methods and FISH), and molecular diagnostic assays. | |||
Laboratory tests of diffuse large B cell lymphoma include:<ref name="”seer”">National Cancer Institute. Surveillance, Epidemiology, and End Results Program 2015. http://seer.cancer.gov</ref><ref name="”seer”">National Cancer Institute. Surveillance, Epidemiology, and End Results Program 2015. http://seer.cancer.gov</ref> | |||
Laboratory tests of diffuse large B cell lymphoma include:<ref name=”seer”>National Cancer Institute. Surveillance, Epidemiology, and End Results Program 2015. http://seer.cancer.gov</ref><ref name=”seer”>National Cancer Institute. Surveillance, Epidemiology, and End Results Program 2015. http://seer.cancer.gov</ref> | |||
* [[Complete blood count]] (CBC) | * [[Complete blood count]] (CBC) | ||
* Blood chemistry studies | * Blood chemistry studies | ||
Line 16: | Line 14: | ||
:*Mutation of ''BCL6'', ''MYC'', ''[[PAX5]]'', ''[[PIM1]]'', ''[[RhoH]]''/''TTFn'', ''[[TP53]]'' genes | :*Mutation of ''BCL6'', ''MYC'', ''[[PAX5]]'', ''[[PIM1]]'', ''[[RhoH]]''/''TTFn'', ''[[TP53]]'' genes | ||
:*Translocations involving ''c-MYC'', ''BCL6'', and ''[[IgH]]'' genes | :*Translocations involving ''c-MYC'', ''BCL6'', and ''[[IgH]]'' genes | ||
* [[Immunophenotyping]] ''BCL-2+'', ''BCL6+/-'', [[CD10]]+, [[CD15]]+, [[CD20]]+, [[CD22]]+, [[CD30]]+, [[CD79a]]+, EBNA-2+, Fox-P1+, [[IRF4]]/MUM1+, LMP-1+, Surface 4 or cytoplasmic [[immunoglobulin]] (Ig) is absent | * [[Immunophenotyping]] ''BCL-2+'', ''BCL6+/-'', MYC, CD5, [[CD10]]+, [[CD15]]+, [[CD20]]+, [[CD22]]+, [[CD30]]+, [[CD79a]]+, EBNA-2+, Fox-P1+, [[IRF4]]/MUM1+, P53, LMP-1+, Surface 4 or cytoplasmic [[immunoglobulin]] (Ig) is absent | ||
==References== | ==References== |
Revision as of 18:13, 11 June 2018
Diffuse large B cell lymphoma Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Diffuse large B cell lymphoma laboratory tests On the Web |
American Roentgen Ray Society Images of Diffuse large B cell lymphoma laboratory tests |
Directions to Hospitals Treating Diffuse large B cell lymphoma |
Risk calculators and risk factors for Diffuse large B cell lymphoma laboratory tests |
DLBCL require a complete work-up includes immunophenotypic analysis, cytogenetic analysis (conventional methods and FISH), and molecular diagnostic assays.
Laboratory tests of diffuse large B cell lymphoma include:[1][1]
- Complete blood count (CBC)
- Blood chemistry studies
- Flow cytometry
- Immunohistochemistry
- Cytology (for primary CNS lymphoma only)
- Genetic testing
- Immunophenotyping BCL-2+, BCL6+/-, MYC, CD5, CD10+, CD15+, CD20+, CD22+, CD30+, CD79a+, EBNA-2+, Fox-P1+, IRF4/MUM1+, P53, LMP-1+, Surface 4 or cytoplasmic immunoglobulin (Ig) is absent
References
- ↑ 1.0 1.1 National Cancer Institute. Surveillance, Epidemiology, and End Results Program 2015. http://seer.cancer.gov